Navigation Links
Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S.
Date:9/23/2010

ng with type 2 diabetes. The PROactive trial demonstrated that although there was no statistically significant difference between ACTOS and standard-of-care alone for the primary endpoint, there was no increase in mortality or total macrovascular events with ACTOS. This safety information has been included in both the FDA-approved product label and EMA-approved Summary of Product Characteristics (SPC) since 2007, providing patients and health care professionals with additional relevant information regarding the CV safety profile of ACTOS.

Takeda is the inventor and developer of ACTOS, which was launched commercially in 1999. ACTOS, as labeled, is an effective and appropriate treatment option for many people living with type 2 diabetes. Certain patients with heart failure should not start taking ACTOS. ACTOS can cause new or worsen heart failure. In clinical trials using ACTOS in monotherapy, the most common adverse events (greater than or equal to 5%) were upper respiratory tract infection, headache, sinusitis, myalgia, tooth disorder, aggravated diabetes mellitus and pharyngitis. Please see additional important safety information continued below.

About ACTOS® (pioglitazone HCl) Indications and Usage

ACTOS is a prescription medication used with diet and exercise to improve blood sugar (glucose) control in adults with type 2 diabetes. ACTOS has been studied as a monotherapy and in combination with sulfonylurea, metformin, or insulin. ACTOS should always be used according to Health Care Provider directions and its Complete Prescribing Information.

Important Safety Information

ACTOS is not for everyone. Certain patients with heart failure should not start taking ACTOS. ACTOS can cause new, or worsen, heart failure. Patients should talk to their doctor immediately if they experience unusually fast weight gain, fluid retention (swelling), shortness of breath, or unusual tiredness.

<
'/>"/>
SOURCE Takeda Pharmaceutical North America, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Arthritis Foundation and Takeda Launch First-Ever National Gout Public Service Announcement (PSA) Campaign, Urging People Living With Gout to Keep Enjoying Lifes Simple Pleasures
2. Orexigen® Therapeutics and Takeda Enter Into Partnership to Commercialize Contrave® in North America
3. Takeda Responds to FDA Advisory Committee Recommendation
4. Takeda Provides Update on Patent Litigation for ACTOS(R) (pioglitazone HCl) and ACTOplus met(R) (pioglitazone HCl and metformin HCl) in the U.S.
5. CellCentric Licenses Novel Epigenetic Discovery Programme to Takeda
6. Amylin and Takeda Announce Decision to Advance Development of Pramlintide/Metreleptin Combination Treatment for Obesity
7. Takeda Announces Initiation of Trial to Study the Concomitant Use of Dexlansoprazole and Other Proton Pump Inhibitors with Plavix(R) (clopidogrel bisulfate)
8. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
9. Takeda San Francisco, Inc. Appoints Michael Buckley, Ph.D. Vice President of Process Sciences
10. Takeda to Establish Four Sales and Marketing Subsidiaries to Expand Its Operations in Mexico, Turkey and Five Other Countries in Europe
11. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... NEW YORK, Aug 20, 2014 Reportlinker.com ... available in its catalogue: Global Patient ... This report analyzes the worldwide markets ... following Product Segments: Floor Scales, Infant & Baby ... report provides separate comprehensive analytics for the US, ...
(Date:8/19/2014)... Aug. 19, 2014   Lincor Inc. ... experience technology to New Jersey ... agreement, CarePoint Health will deploy Lincor,s PatientLINC technology ... Christ Hospital and Hoboken University Medical Center. ... of software solutions to help hospitals reach new ...
(Date:8/19/2014)... , Aug. 19, 2014 /PRNewswire-iReach/ -- ChemImage founder ... present a scientific poster describing an innovative diagnostic procedure ... 2014: Shedding New Light on Disease (SPEC) conference in ... Dr. Treado,s poster entitled, "Development of in vitro Diagnostics ... will be discussed during the conference poster session on ...
Breaking Medicine Technology:Global Patient Scales Industry 2Global Patient Scales Industry 3Global Patient Scales Industry 4Global Patient Scales Industry 5Global Patient Scales Industry 6Global Patient Scales Industry 7Global Patient Scales Industry 8Global Patient Scales Industry 9Global Patient Scales Industry 10Global Patient Scales Industry 11Global Patient Scales Industry 12Global Patient Scales Industry 13Global Patient Scales Industry 14Global Patient Scales Industry 15Global Patient Scales Industry 16Global Patient Scales Industry 17Global Patient Scales Industry 18Global Patient Scales Industry 19Lincor Announces Agreement With CarePoint Health For State-Of-The-Art Patient Engagement Technology 2ChemImage Scientists Present Latest Developments for in vitro Detection of Colorectal Cancer Using Raman Molecular Imaging (RMI) at International Conference Focused on Biomedical Applications of Raman Spectroscopy 2
... CINCINNATI, Ohio , June 29 Dr. Harry J. ... speaker and panel discussion participant at the 2010 Central Regional Meeting of ... June 16-19, 2010 .  The 2010 CeRMACS attracted over 400 participants and ... chemical disciplines.   , , ...
... /PRNewswire-Asia-FirstCall/ -- Dehaier Medical Systems,Ltd. (Nasdaq: DHRM ), an emerging leader in the ... ,today announced members of its Executive Management will ring the NASDAQ Stock,Market closing bell ... , , ... , , ...
Cached Medicine Technology:Dr. Harry J. Guttman, Esq. Invited Speaker at 2010 Central Regional Meeting of the American Chemical Society 2Dehaier Medical Systems Chief Executive Officer To Ring NASDAQ Stock Market Closing Bell 2Dehaier Medical Systems Chief Executive Officer To Ring NASDAQ Stock Market Closing Bell 3
(Date:8/20/2014)... August 20, 2014 According to an ... August 7 in the multicounty litigation (MCL) case pending ... DEPUY ASR HIP IMPLANTS LITIGATION; no. BER-L-3971-11), nearly 350 ... been dismissed without prejudice. The cases enumerated in the ... being resolved.” The Rottenstein Law Group LLP, a national ...
(Date:8/20/2014)... made it easier to predict both breast cancer ... of a unique gene. The newly found marker ... and customise a treatment regimen that is more ... scientists from A*STAR,s Institute of Molecular and Cell ... Singapore (CSI Singapore) at the National University of ...
(Date:8/20/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... DETECTORS: TECHNOLOGIES AND GLOBAL MARKETS , the global ... grow to $15.2 billion by 2019, with a ... Increasing industrialization is driving significant growth across ... range of industrial applications such as military and ...
(Date:8/20/2014)... 2014 The finalists are in for ... industry trade magazine, will honor the pharmaceutical industry’s most ... given to outstanding companies, marketers and brand managers representing ... “We are proud to announce that we received our ... double the number of submissions we received last year,” ...
(Date:8/20/2014)... Mateo, CA (PRWEB) August 20, 2014 ... newest product—the Really Little Green Pouch —to meet ... to feed babies and toddlers homemade foods. , ... Little Green Pouch co-founder Maggie Crawford. She continues, ... kids, to limit exposure to things like pesticides and ...
Breaking Medicine News(10 mins):Health News:350 NJ DePuy ASR Lawsuits Dismissed Pending Settlement Talks, Notes Rottenstein Law Group LLP 2Health News:Novel gene predicts both breast cancer relapse and response to chemotherapy 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 2Health News:Global Market for Photonic Sensors and Detectors to Reach $15.2 Billion in 2019 3Health News:PM360 Announces 2014 Trailblazer Award Finalists 2Health News:PM360 Announces 2014 Trailblazer Award Finalists 3Health News:PM360 Announces 2014 Trailblazer Award Finalists 4Health News:PM360 Announces 2014 Trailblazer Award Finalists 5Health News:PM360 Announces 2014 Trailblazer Award Finalists 6Health News:PM360 Announces 2014 Trailblazer Award Finalists 7Health News:PM360 Announces 2014 Trailblazer Award Finalists 8Health News:Little Green Pouch Launches New Product to Help Health-conscious Parents Reduce Babies’ Eco-footprint 2
... Dec. 20 HMS Holdings Corp. (Nasdaq:,HMSY) today announced ... Conference, which will be held January 7-10, 2008 at ... http://www.newscom.com/cgi-bin/prnh/20030304/NYTU172LOGO ), Robert Holster, Chairman and CEO ... at 2:00 p.m. Pacific Time., A live broadcast ...
... to determine if treating depression improves health of ... heart ... with heart,disease are more likely to suffer from depression than those ... well understood,but it is known that depression in heart patients is ...
... THURSDAY, Dec. 20 (HealthDay News) -- Exposure to secondhand ... of developing allergies, Swedish researchers say. , A team ... by the parents of more than 4,000 families. , ... were ages two months, 12 months, 2 years and ...
... Toronto Stock Exchange Symbol: AKL, MONTREAL, Dec. ... drug development company focused on developing therapies for ... to unfavorable market,conditions, particularly in the small and ... public offering initiative. The Company is currently,contemplating other ...
... University researchers have updated their Food Guide Pyramid for ... now known as MyPyramid. The Tufts version is specifically ... and content. The Modified MyPyramid for Older Adults continues ... fluid balance, but has added additional guidance about forms ...
... WESTBROOK, Maine, Dec. 19 IDEXX Laboratories,Inc. (Nasdaq: ... the,JPMorgan 26th Annual Healthcare Conference. Jonathan W. Ayers, Chairman,President ... the Company on,Monday, January 7, 2008 at 8:00 a.m. ... Individuals can access the live audio webcast of,the presentation ...
Cached Medicine News:Health News:Blue Cross Blue Shield of Michigan Foundation Funds Study Exploring Link between Heart Disease and Depression 2Health News:Parents' Smoking Boosts Child's Allergy Risk 2Health News:Akela Pharma provides corporate update 2Health News:Tufts researchers update their food guide pyramid for older adults 2Health News:Tufts researchers update their food guide pyramid for older adults 3
Bi-phasic peristaltic infusion pump for tumescent work....
Inquire...
... Pump provides optimum flow rate ... Operates on any voltage worldwide. ... safety Interlock and easy load ... Double Spike Tubing, Dual Pneumatic ...
... VASER System represents a major advance ... to cosmetic procedures. Combined with precision ... emulsification, a solid grooved probe design ... System has been designed to minimize ...
Medicine Products: